Repatha Mental Health and Mood Impact: What the Evidence Actually Shows

What the Repatha label says about mood and the brain

Repatha is a human monoclonal IgG2 antibody that binds PCSK9, a protein that normally pushes LDL receptors toward degradation in the liver. Blocking it leaves more receptors free to pull LDL out of the blood [1]. It is injected under the skin at 140 mg every 2 weeks or 420 mg once monthly, and in the FOURIER trial it was added to statin therapy [1][3].

The label carries no boxed warning. Its only Warning and Precaution covers hypersensitivity reactions including angioedema, and the label says to stop treatment and treat if serious symptoms occur [1]. The adverse reactions it reports include nasopharyngitis, upper respiratory tract infection, influenza, back pain, injection site reactions, cough, urinary tract infection, sinusitis, headache, myalgia and dizziness; depression, anxiety, suicidality and cognitive impairment are not among them [1]. Post-marketing reports added angioedema and influenza-like illness [1].

The two reactions closest to a mental-health question are headache and dizziness. In the label's 52-week placebo-controlled trial of 599 people on Repatha 420 mg monthly versus 302 on placebo, headache occurred in 4.0% versus 3.6% and dizziness in 3.7% versus 2.6% [1]. In FOURIER (13,784 on evolocumab versus 13,780 on placebo, median 24.8 months of exposure), the most common events were diabetes mellitus 8.8% versus 8.2%, nasopharyngitis 7.8% versus 7.4%, and upper respiratory infection 5.1% versus 4.8% [1][3].

What EBBINGHAUS actually measured

EBBINGHAUS was a cognitive substudy of FOURIER. The label records 1,974 patients enrolled; the published analysis followed 1,204 people for a median of 19 months [1][2]. Testing used the Cambridge Neuropsychological Test Automated Battery at baseline, week 24, yearly, and at the end of the trial [2].

The primary endpoint was the spatial working memory strategy index of executive function, scored 4 to 28 with lower scores indicating more efficient strategy and planning [2]. Mean change from baseline was -0.21 with evolocumab and -0.29 with placebo, and evolocumab met the prespecified non-inferiority margin, with P<0.001 for the non-inferiority comparison [2]. That margin was set at 20% of the standard deviation of the placebo score [2]. Secondary endpoints were working memory, episodic memory and psychomotor speed [2], and the label adds that evolocumab was also non-inferior on selected other cognitive domains [1].

Non-inferiority is a statement about a margin, not proof of zero effect. It means this substudy did not find a cognitive difference larger than the prespecified margin.

Does very low LDL cholesterol on Repatha affect the brain?

In FOURIER, median LDL-C fell from 92 mg/dL to 30 mg/dL at 48 weeks, a 59% reduction compared with placebo [3]. The label reports a 57% difference at week 72, a median of 26 mg/dL at week 48, and 47% of patients below 25 mg/dL [1]. Concern about cognition with PCSK9 inhibitors and low LDL cholesterol is what prompted the substudy [2].

The cognitive substudy ran inside this trial, where median LDL-C reached 30 mg/dL, and evolocumab was non-inferior to placebo on executive function and other tested domains [3][2]. In VESALIUS-CV, which randomized 12,257 people with atherosclerosis or diabetes and no prior myocardial infarction or stroke and followed them a median of 4.6 years, there was no evidence of a between-group difference in safety events [4].

Repatha alongside antidepressants and other psychiatric drugs

The Repatha label does not include a drug-interactions section and states that evolocumab is eliminated by target binding and proteolysis [1]. Adults taking a high-intensity statin had about 20% lower Cmax and AUC of evolocumab, which the label calls not clinically meaningful [1]. Age, sex, race and creatinine clearance did not affect its pharmacokinetics, and no dose adjustment is needed for renal impairment or mild to moderate hepatic impairment [1].

What is not known

EBBINGHAUS followed people for a median of 19 months and assessed cognitive function, not mood or depression [2]. The reassurance here rests on a cognitive battery that came back non-inferior and on a label whose reported adverse reactions have no psychiatric entries, not on direct measurement of mood in people taking evolocumab.